These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26860858)

  • 1. CAR T-cell therapy: opportunities and challenges.
    Zhang W
    Immunotherapy; 2016; 8(3):245-7. PubMed ID: 26860858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T-cell therapy: toxicity and the relevance of preclinical models.
    Kalaitsidou M; Kueberuwa G; Schütt A; Gilham DE
    Immunotherapy; 2015; 7(5):487-97. PubMed ID: 26065475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Armed T cells with CAR for cancer immunotherapy.
    Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
    [No Abstract]   [Full Text] [Related]  

  • 4. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor T cells: a novel therapy for solid tumors.
    Yu S; Li A; Liu Q; Li T; Yuan X; Han X; Wu K
    J Hematol Oncol; 2017 Mar; 10(1):78. PubMed ID: 28356156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
    Shirasu N; Kuroki M
    Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive therapy with CAR redirected T cells for hematological malignancies.
    Li S; Yang Z; Shen J; Shan J; Qian C
    Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
    Lipowska-Bhalla G; Gilham DE; Hawkins RE; Rothwell DG
    Cancer Immunol Immunother; 2012 Jul; 61(7):953-62. PubMed ID: 22527245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.
    Atanackovic D; Radhakrishnan SV; Bhardwaj N; Luetkens T
    Br J Haematol; 2016 Mar; 172(5):685-98. PubMed ID: 26791002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
    Luskin MR; DeAngelo DJ
    Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
    Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
    Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CARTs for Solid Tumors: Feasible or Infeasible?
    Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q
    Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
    Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
    Jindal V; Arora E; Gupta S
    Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy.
    Tang XJ; Sun XY; Huang KM; Zhang L; Yang ZS; Zou DD; Wang B; Warnock GL; Dai LJ; Luo J
    Oncotarget; 2015 Dec; 6(42):44179-90. PubMed ID: 26496034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.
    You F; Jiang L; Zhang B; Lu Q; Zhou Q; Liao X; Wu H; Du K; Zhu Y; Meng H; Gong Z; Zong Y; Huang L; Lu M; Tang J; Li Y; Zhai X; Wang X; Ye S; Chen D; Yuan L; Qi L; Yang L
    Sci China Life Sci; 2016 Apr; 59(4):386-97. PubMed ID: 26961900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.